BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34006094)

  • 1. Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.
    Jain S; Xun G; Abesteh S; Ho S; Lingamaneni M; Martin TA; Tasan I; Yang C; Zhao H
    ACS Synth Biol; 2021 Jun; 10(6):1320-1327. PubMed ID: 34006094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution structure and dynamics of anti-CRISPR AcrIIA4, the Cas9 inhibitor.
    Kim I; Jeong M; Ka D; Han M; Kim NK; Bae E; Suh JY
    Sci Rep; 2018 Mar; 8(1):3883. PubMed ID: 29497118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR Guide RNA Design Guidelines for Efficient Genome Editing.
    Schindele P; Wolter F; Puchta H
    Methods Mol Biol; 2020; 2166():331-342. PubMed ID: 32710418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disabling Cas9 by an anti-CRISPR DNA mimic.
    Shin J; Jiang F; Liu JJ; Bray NL; Rauch BJ; Baik SH; Nogales E; Bondy-Denomy J; Corn JE; Doudna JA
    Sci Adv; 2017 Jul; 3(7):e1701620. PubMed ID: 28706995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Activation of Guide RNAs to Enable Successive CRISPR-Cas9 Activities.
    Clarke R; Terry AR; Pennington H; Hasty C; MacDougall MS; Regan M; Merrill BJ
    Mol Cell; 2021 Jan; 81(2):226-238.e5. PubMed ID: 33378644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA stretching induces Cas9 off-target activity.
    Newton MD; Taylor BJ; Driessen RPC; Roos L; Cvetesic N; Allyjaun S; Lenhard B; Cuomo ME; Rueda DS
    Nat Struct Mol Biol; 2019 Mar; 26(3):185-192. PubMed ID: 30804513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phage AcrIIA2 DNA Mimicry: Structural Basis of the CRISPR and Anti-CRISPR Arms Race.
    Liu L; Yin M; Wang M; Wang Y
    Mol Cell; 2019 Feb; 73(3):611-620.e3. PubMed ID: 30606466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Assembly of CRISPR/Cas9 Lentiviral and rAAV Vectors for Targeted Genome Editing.
    Sandoval IM; Collier TJ; Manfredsson FP
    Methods Mol Biol; 2019; 1937():29-45. PubMed ID: 30706388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precise and Predictable CRISPR Chromosomal Rearrangements Reveal Principles of Cas9-Mediated Nucleotide Insertion.
    Shou J; Li J; Liu Y; Wu Q
    Mol Cell; 2018 Aug; 71(4):498-509.e4. PubMed ID: 30033371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optical Control of Genome Editing by Photoactivatable Cas9.
    Otabe T; Nihongaki Y; Sato M
    Methods Mol Biol; 2021; 2312():225-233. PubMed ID: 34228293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationally Designed Anti-CRISPR Nucleic Acid Inhibitors of CRISPR-Cas9.
    Barkau CL; O'Reilly D; Rohilla KJ; Damha MJ; Gagnon KT
    Nucleic Acid Ther; 2019 Jun; 29(3):136-147. PubMed ID: 30990769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence.
    Babu K; Kathiresan V; Kumari P; Newsom S; Parameshwaran HP; Chen X; Liu J; Qin PZ; Rajan R
    Biochemistry; 2021 Dec; 60(49):3783-3800. PubMed ID: 34757726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.
    Hiranniramol K; Chen Y; Wang X
    Methods Mol Biol; 2020; 2115():351-364. PubMed ID: 32006410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.